Tag: colitis
OSE Immunotherapeutics announces the end of recruitment in the Phase 2 clinical study of Lusvertikimab evaluated in patients suffering from ulcerative colitis – 03/18/2024 at 07:30
Nantes, France – March 18, 2024, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces the end of recruitment in the Phase 2b clinical trial evaluating the…
Eli Lilly: FDA approves its treatment for ulcerative colitis – 10/27/2023 at 2:41 p.m.
(AOF) – Eli Lilly and Company announced today that the Food and Drug Administration (FDA) has approved Omvo (mirikizumab-mrkz) infusion for the treatment of moderately to severely active ulcerative colitis…
Abivax highlights its clinical development program for obefazimod in ulcerative colitis
By Claude Leguilloux Published on 02/10/2023 at 6:49 p.m. Photo credit © Abivax (Boursier.com) — Abivax SA, a…
Bristol Myers: Ulcerative Colitis Education Campaign
(CercleFinance.com) – Bristol Myers Squibb has launched Supporting You with UC, an educational campaign on ulcerative colitis (UC) with Rosie White, Patient Ambassador, Women’s World Cup commentator, former professional soccer…
OSE Immunotherapeutics pursues clinical development in ulcerative colitis with full worldwide rights to Lusvertikimab – 05/12/2023 at 18:00
• Lusvertikimab (OSE-127), a ‘first-in-class’ product, is the most clinically advanced anti-IL-7R monoclonal antibody. • Ongoing phase 2 trial in ulcerative colitis (sponsor OSE Immunotherapeutics) after a positive futility analysis…
Abivax includes the first patient in the United States in its global phase 3 program with obefazimod in ulcerative colitis. – 10/11/2022 at 6:06 p.m.
ABIVAX press release Abivax includes the first patient in the United States in its global phase 3 program with obefazimod in ulcerative colitis. First patient included in the United States…
J&J: the promise of Stelara in ulcerative colitis
(CercleFinance.com) – J&J today presented final long-term (LTE) data from a Phase 3 study demonstrating the efficacy and safety of Stelara (ustekinumab) over four years of treatment in adult patients…
ABIVAX: The phase 3 clinical program with Obefazimod in ulcerative colitis is progressing after the approval of the IRB in the United States. – 04/08/2022 at 18:05
ABIVAX press release ABIVAX: The phase 3 clinical program with Obefazimod in ulcerative colitis is progressing after the approval of the IRB in the United States. The protocols for the…
Ulcerative colitis: cause, symptom, treatment of this chronic inflammatory bowel disease (IBD): Femme Actuelle Le MAG
Ulcerative colitis: cause, symptom, treatment of this chronic inflammatory bowel disease (IBD): Femme Actuelle Le MAG Path 2 645DBCB3-7979-441A-BA4B-98E7BF17E1BE 1785B508-2A96-4CF5-AA87-79B0FE0441BF advertisement source site-45
Abivax announces excellent efficacy and safety results after one year of treatment in the phase 2b maintenance study of ABX464 in ulcerative colitis. – 04/06/2022 at 6:05 p.m.
ABIVAX press release Abivax announces excellent efficacy and safety results after one year of treatment in the phase 2b maintenance study of ABX464 in ulcerative colitis. The interim analysis shows…
Stool transplant • Help with diarrhea & ulcerative colitis
Complicated diarrheal diseases are increasing – and they can be fatal. Healing brings donor faeces into the damaged intestinal flora (stool transplant). This treatment should now become the standard, experts…